CD25 Is Expressed by Canine Cutaneous Mast Cell Tumors but not by Cutaneous Connective Tissue Mast Cells

Veterinary Pathology

Volumn 49, Issue 6, 2012, Pages 988-997

  Meyer, A ^a   Gruber, A D ^a   Klopfleisch, R ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

carcinogenesis; CD25; dog; immunofluorescence; immunohistochemistry; interleukin 2 receptor; mast cell tumor

Indexed keywords

DNA; INTERLEUKIN 2 RECEPTOR ALPHA; MESSENGER RNA; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ANIMAL; CANCER GRADING; CARCINOGENESIS; CONNECTIVE TISSUE; DOG; DOG DISEASE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; MAST CELL; METABOLISM; MUTATION; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN TUMOR; VETERINARY;

ANIMALS; CARCINOGENESIS; CONNECTIVE TISSUE; DNA, NEOPLASM; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MAST CELLS; MUTATION; NEOPLASM GRADING; PROTO-ONCOGENE PROTEINS C-KIT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84868692680     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985812439215     Document Type: Article

References (46)

1. Ambrosetti A,Nadali G,Vinante F,et al.Soluble interleukin-2 receptor in hairy-cell leukemia: a reliable marker of disease.Int J Clin Lab Res. 1993;23:34-37.
2. Baumgartner C,Sonneck K,Krauth MT,et al.Immunohistochemical assessment of CD25 is equally sensitive and diagnostic in mastocytosis compared to flow cytometry.Eur J Clin Invest. 2008;38:326-335.
3. Bien E,Balcerska A.Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review.Biomarkers. 2008;13:1-26.
4. Caligiuri MA,Zmuidzinas A,Manley TJ,et al.Functional consequences of interleukin 2 receptor expression on resting human lymphocytes: identification of a novel natural killer cell subset with high affinity receptors.J Exp Med. 1990;171:1509-1526.
5. Driesen J,Popov A,Schultze JL.CD25 as an immune regulatory molecule expressed on myeloid dendritic cells.Immunobiology. 2008;213:849-858.
6. Escribano L,Diaz-Agustin B,Bellas C,et al.Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis.Leuk Res. 2001;25:563-570.
7. Escribano L,Orfao A,Diaz-Agustin B,et al.Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications.Blood. 1998;91:2731-2736.
8. Froberg GK,Lindberg R,Ritter M,et al.Expression of serotonin and its 5-HT1A receptor in canine cutaneous mast cell tumours.J Comp Pathol. 2009;141:89-97.
9. Goto H,Tsurumi H,Takemura M,et al.Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.J Cancer Res Clin Oncol. 2005;131:73-79.
10. Hahn HP,Hornick JL.Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis.Am J Surg Pathol. 2007;31:1669-1676.
11. Hollmann TJ,Brenn T,Hornick JL.CD25 expression on cutaneous mast cells from adult patients presenting with urticaria pigmentosa is predictive of systemic mastocytosis.Am J Surg Pathol. 2008;32:139-145.
12. Horiuchi S,Koyanagi Y,Tanaka Y,et al.Altered interleukin-2 receptor alpha-chain is expressed in human T-cell leukaemia virus type-I-infected T-cell lines and human peripheral blood mononuclear cells of adult T-cell leukaemia patients through an alternative splicing mechanism.Immunology. 1997;91:28-34.
13. Horny HP,Bennett JWHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:54-63.Swerdlow SHCampo EHarris NL, ed. Lyon, France: IARC Press; 2008:54-63.
14. Huang A,Quinn H,Glover C,et al.The presence of interleukin-2 receptor alpha in the serum of colorectal cancer patients is unlikely to result only from T cell up-regulation.Cancer Immunol Immunother. 2002;51:53-57.
15. Jones CL,Grahn RA,Chien MB,et al.Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis.J Vet Diagn Invest. 2004;16:95-100.
16. Jordan JH,Walchshofer S,Jurecka W,et al.Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).Hum Pathol. 2001;32:545-552.
17. Kallio JP,Tammela TL,Marttinen AT,et al.Soluble immunological parameters and early prognosis of renal cell cancer patients.J Exp Clin Cancer Res. 2001;20:523-528.
18. Kiupel M,Webster JD,Bailey KL,et al.Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior.Vet Pathol. 2010;48:147-155.
19. Klopfleisch R,Gruber AD.Increased expression of BRCA2 and RAD51 in lymph node metastases of canine mammary adenocarcinomas.Vet Pathol. 2009;46:416-422.
20. Klopfleisch R,Hvid H,Klose P,et al.Insulin receptor is expressed in normal canine mammary gland and benign adenomas but decreased in metastatic canine mammary carcinomas similar to human breast cancer.Vet Comp Oncol. 2010;8:293-301.
21. Klopfleisch R,Lenze D,Hummel M,et al.Metastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profiles.BMC Cancer. 2010;10:618.
22. Klopfleisch R,Lenze D,Hummel M,et al.The metastatic cascade is reflected in the transcriptome of metastatic canine mammary carcinomas.Vet J. 2011;190:236-243.
23. Krokowski M,Sotlar K,Krauth MT,et al.Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia.Am J Clin Pathol. 2005;124:560-568.
24. Letard S,Yang Y,Hanssens K,et al.Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors.Mol Cancer Res. 2008;6:1137-1145.
25. Letourneau S,Krieg C,Pantaleo G,et al.IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets.J Allergy Clin Immunol. 2009;123:758-762.
26. Lin TY,London CA.Characterization and modulation of canine mast cell derived eicosanoids.Vet Immunol Immunopathol. 2010;135:118-127.
27. London CA,Galli SJ,Yuuki T,et al.Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit.Exp Hematol. 1999;27:689-697.
28. Malek TR.The biology of interleukin-2.Annu Rev Immunol. 2008;26:453-479.
29. Olejniczak K,Kasprzak A.Biological properties of interleukin 2 and its role in pathogenesis of selected diseases-a review.Med Sci Monit. 2008;14:RA179-RA189.
30. Ottaiano A,Leonardi E,Simeone E,et al.Soluble interleukin-2 receptor in stage I-III melanoma.Cytokine. 2006;33:150-155.
31. Patnaik AK,Ehler WJ,MacEwen EG.Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs.Vet Pathol. 1984;21:469-474.
32. Poggi A,Zocchi MR.Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.Arch Immunol Ther Exp (Warsz). 2006;54:323-333.
33. Rimoldi D,Salvi S,Hartmann F,et al.Expression of IL-2 receptors in human melanoma cells.Anticancer Res. 1993;13:555-564.
34. Sotlar K,Horny HP,Simonitsch I,et al.CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens.Am J Surg Pathol. 2004;28:1319-1325.
35. Valent P,Horny HP,Escribano L,et al.Diagnostic criteria and classification of mastocytosis: a consensus proposal.Leuk Res. 2001;25:603-625.
36. van Daele PL,Beukenkamp BS,Geertsma-Kleinekoort WM,et al.Immunophenotyping of mast cells: a sensitive and specific diagnostic tool for systemic mastocytosis.Neth J Med. 2009;67:142-146.
37. Velten FW,Rambow F,Metharom P,et al.Enhanced T-cell activation and T-cell-dependent IL-2 production by CD83+, CD25high, CD43 high human monocyte-derived dendritic cells.Mol Immunol. 2007;44:1544-1550.
38. von Bergwelt-Baildon MS,Popov A,Saric T,et al.CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition.Blood. 2006;108:228-237.
39. Wang J,Wicker LS,Santamaria P.IL-2 and its high-affinity receptor: genetic control of immunoregulation and autoimmunity.Semin Immunol. 2009;21:363-371.
40. Wang LS,Chow KC,Li WY,et al.Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma.Clin Cancer Res. 2000;6:1445-1451.
41. Webster JD,Kiupel M,Kaneene JB,et al.The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors.Vet Pathol. 2004;41:371-377.
42. Webster JD,Yuzbasiyan-Gurkan V,Kaneene JB,et al.The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors.Neoplasia. 2006;8:104-111.
43. Webster JD,Yuzbasiyan-Gurkan V,Miller RA,et al.Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication.Vet Pathol. 2007;44:298-308.
44. Weiss AT,Delcour NM,Meyer A,et al.Efficient and cost-effective extraction of genomic DNA from formalin-fixed and paraffin-embedded tissues.Vet Pathol. 2011;48:834-838.
45. Yano T,Fukuyama Y,Yokoyama H,et al.Interleukin-2 receptors in pulmonary adenocarcinoma tissue.Lung Cancer. 1996;16:13-19.
46. Zemke D,Yamini B,Yuzbasiyan-Gurkan V.Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs.Vet Pathol. 2002;39:529-535.